Deals in Depth: October 2008
October 2008 dealmaking highlights: China Medical's purchase of the HPV-DNA biosensor chip and SPR technology from Molecular Diagnostics Technologies for $345 million was the leading alliance in terms of $ value. Eli Lilly emerged as the mystery bidder for ImClone, defeating BMS and signing a definitive agreement to buy the biotech for $6.5 billion. In October no FOPOs or IPOs were completed in either industry. Private placements, mostly from early- and late-VC rounds, in biopharmas decreased 31% from last month to $358 million while investments in medical devices were up 1.5x to $296 million.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.